Literature DB >> 24829463

Chronic kidney disease rather than illness severity predicts medium- to long-term mortality and renal outcome after acute kidney injury.

Mark Findlay1, Ken Donaldson1, Sue Robertson1, Alison Almond1, Robert Flynn2, Chris Isles3.   

Abstract

BACKGROUND: Acute kidney injury (AKI) requiring renal replacement therapy (RRT) continues to be associated with a hospital mortality of ∼50%. Longer-term outcomes have been less well studied. We sought to determine the influence of ventilation and of underlying chronic kidney disease (CKD) on medium and longterm mortality and renal outcomes.
METHODS: All patients requiring RRT for AKI in south west Scotland between 1 January 1994 and 31 December 2005 were followed prospectively. Survival of patients who were and were not ventilated and of those with and without underlying CKD was compared by odds ratio (OR), adjusting for age and sex. Renal outcomes were determined by interrogation of our biochemistry database.
RESULTS: Three hundred and ninety-six patients with AKI received RRT. One hundred and seventy-six (44%) were ventilated and 98 (25%) had underlying CKD. Patients who required ventilation had a significantly worse 90-day survival than those who did not (OR 2.10 for death; 95% CI 1.34, 3.29) whereas underlying CKD did not predict such an early adverse outcome (OR 1.49; 95% CI 0.89, 2.50). By 5 years, patients who had been ventilated during the acute illness were no longer at increased risk (OR 0.79; 95% CI 0.38, 1.62) whereas the adverse effect of underlying CKD was statistically significant (OR 6.05; 95% CI 2.23, 16.5). Underlying CKD was also a strong predictor of the need for RRT during follow-up.
CONCLUSION: In an unselected series of patients with AKI requiring RRT, underlying CKD rather than illness severity predicted medium- to long-term mortality.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  acute kidney injury; acute on chronic kidney disease; renal outcomes; survival

Mesh:

Year:  2014        PMID: 24829463     DOI: 10.1093/ndt/gfu185

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms.

Authors:  Liyu He; Qingqing Wei; Jing Liu; Mixuan Yi; Yu Liu; Hong Liu; Lin Sun; Youming Peng; Fuyou Liu; Manjeri A Venkatachalam; Zheng Dong
Journal:  Kidney Int       Date:  2017-09-08       Impact factor: 10.612

2.  Diagnosis of acute kidney injury and its association with in-hospital mortality in patients with infective exacerbations of bronchiectasis: cohort study from a UK nationwide database.

Authors:  Masao Iwagami; Kathryn Mansfield; Jennifer Quint; Dorothea Nitsch; Laurie Tomlinson
Journal:  BMC Pulm Med       Date:  2016-01-19       Impact factor: 3.317

3.  Three-year mortality in 30-day survivors of critical care with acute kidney injury: data from the prospective observational FINNAKI study.

Authors:  Henriikka Mildh; Ville Pettilä; Anna-Maija Korhonen; Sari Karlsson; Tero Ala-Kokko; Matti Reinikainen; Suvi T Vaara
Journal:  Ann Intensive Care       Date:  2016-11-29       Impact factor: 6.925

4.  Impact of acute kidney injury on long-term mortality and progression to chronic kidney disease among critically ill children.

Authors:  Najlaa G Al-Otaibi; Maryam Zeinelabdin; Mohamed A Shalaby; Norah Khathlan; Ghadi D Mashat; Amal A Zahrani; Sundus Mw NoorSaeed; Nora M Shalabi; Khalid A Alhasan; Sara N Sharief; Amr S Albanna; Jameela A Kari
Journal:  Saudi Med J       Date:  2017-02       Impact factor: 1.484

5.  Long-Term Preservation of Renal Function in Septic Shock Burn Patients Requiring Renal Replacement Therapy for Acute Kidney Injury.

Authors:  Filippo Mariano; Consuelo De Biase; Zsuzsanna Hollo; Ilaria Deambrosis; Annalisa Davit; Alberto Mella; Daniela Bergamo; Stefano Maffei; Francesca Rumbolo; Alberto Papaleo; Maurizio Stella; Luigi Biancone
Journal:  J Clin Med       Date:  2021-12-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.